AmerisourceBergen Stock Hits New 52-Week High (ABC)

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

NEW YORK ( TheStreet) -- AmerisourceBergen (NYSE: ABC) hit a new 52-week high Wednesday as it is currently trading at $55.03, above its previous 52-week high of $54.99 with 2.4 million shares traded as of 3:30 p.m. ET. Average volume has been 2.5 million shares over the past 30 days.

AmerisourceBergen has a market cap of $12.44 billion and is part of the services sector and wholesale industry. Shares are up 27.3% year to date as of the close of trading on Tuesday.

AmerisourceBergen Corporation, a pharmaceutical services company, provides drug distribution and related services to healthcare providers and pharmaceutical manufacturers primarily in the United States and Canada. The company has a P/E ratio of 19, above the S&P 500 P/E ratio of 17.7.

  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

TheStreet Ratings rates AmerisourceBergen as a buy. The company's strengths can be seen in multiple areas, such as its growth in earnings per share, notable return on equity, good cash flow from operations, increase in net income and increase in stock price during the past year. We feel these strengths outweigh the fact that the company shows low profit margins. You can view the full AmerisourceBergen Ratings Report.

See all 52-week high stocks or get investment ideas from our investment research center.

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100% See his top picks for 14-days FREE.
null

If you liked this article you might like

How You Can Beat the Still Astronomical Prices for Prescription Drugs

Teva's Massive Debt Load Just Became an Even Bigger Issue

Teva Shares Are Getting Obliterated Again After Vicious Investment Bank Downgrades

Teva Shares Are Taking a Beating and Dragging Down the Generic Drugmakers

Walgreens Takes Piece of PharMerica, Quest to Dominate Healthcare Continues